摘要
目的探究玻璃体腔内注射曲安奈德与康柏西普治疗2型糖尿病(T2DM)致视网膜病变的临床疗效及对患者预后的影响。方法选取2019年2月至2020年2月本院收治的76例T2DM致视网膜病变患者作为研究对象,采用单双数标记法分为曲安奈德组和康柏西普组,各38例。曲安奈德组给予玻璃体腔内注射曲安奈德,康柏西普组给予玻璃体腔内注射康柏西普,比较两组临床疗效、治疗前后最佳矫正视力(BCVA)和视网膜厚度及并发症发生率。结果康柏西普组治疗总有效率(97.37%)高于曲安奈德组(81.58%),差异有统计学意义(P<0.05)。治疗后,两组最佳矫正视力大于治疗前,视网膜厚度薄于治疗前,且康柏西普组最佳矫正视力大于曲安奈德组,视网膜厚度薄于曲安奈德组,差异有统计学意义(P<0.05)。康柏西普组并发症发生率(7.89%)低于曲安奈德组(28.95%),差异有统计学意义(P<0.05)。结论玻璃体腔内注射康柏西普治疗T2DM致视网膜病变疗效显著,可改善患者最佳矫正视力和视网膜厚度,减少术后并发症的发生,值得临床推广应用。
Objective To investigate the clinical efficacy of intravitreal injection of triamcinolone acetonide and conbercept in the treatment of retinopathy caused by type 2 diabetes(T2DM)and its impact on prognosis.Methods 76 patients with retinopathy caused by T2DM who were admitted to our hospital from February 2019 to February 2020 were selected as the study subjects,and they were divided into triamcinolone acetonide group and conbercept group according to single and even number labeling method,with 38 cases in each group.Triamcinolone acetonide group was given intravitreal injection of triamcinolone acetonide,and conbercept group was given intravitreal injection of conbercept.The clinical efficacy,best corrected visual acuity(BCVA),retinal thickness before and after treatment and incidence of complications were compared between the two groups.Results The total effective rate in the conbercept group(97.37%)was higher than that in the triamcinolone acetonide group(81.58%),and the difference was statistically significant(P<0.05).After treatment,the best corrected visual acuity of the two groups was greater than that before treatment,and the retinal thickness was thinner than that before treatment,and the best corrected visual acuity of the conbercept group was greater than that of the triamcinolone acetonide group,and the retinal thickness was thinner than that of the triamcinolone acetonide group,and the difference was statistically significant(P<0.05).The incidence of complications of conbercept group(7.89%)was lower than that of triamcinolone acetonide group(28.95%),and the difference was statistically significant(P<0.05).Conclusion Intravitreal injection of conbercept in the treatment of retinopathy caused by T2DM has significant effect,which can improve the best corrected visual acuity and retinal thickness of patients,reduce the occurrence of postoperative complications,which is worthy of clinical promotion and application.
作者
潘学良
PAN Xueliang(Department of Ophthalmology,Liaoyang Central Hospital,Liaoyang,Liaoning,111000,China)
出处
《当代医学》
2022年第26期128-131,共4页
Contemporary Medicine
